Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03570827 | Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy | completed | Phase 2 | 53 | Mayo ClinicOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT03941756 | Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | recruiting | N/A | 252 | M.D. Anderson Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04648904 | Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer | active not recruiting | Early Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05496959 | 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study(LUNAR) | active not recruiting | Phase 2 | 93 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | terminated | Phase 3 | 174 | Abnoba GmbhINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03503643 | Hemi-Gland Cryoablation for Prostate Cancer at UCLA | completed | — | 354 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04687969 | Multimodal Machine Learning Characterization of Solid Tumors | completed | — | 50 | Ciprian Catana, MD, PhDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04811703 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer(PIPACOVA) | recruiting | Phase 1 | 15 | Hospices Civils de LyonOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05931419 | High-Risk prostatE Cancer radiatiOn Versus surgERy(RECOVER) | recruiting | — | 837 | Comprehensive Cancer Centre The NetherlandsOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07468903 | Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer | recruiting | N/A | 45 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT06305299 | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | recruiting | Phase 1 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT03933670 | Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 60 | University of California, San FranciscoOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT07593339 | Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery | not yet recruiting | N/A | 30 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 0 | May 18, 2026 | clinicaltrials |
| NCT00544830 | Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04622319 | A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) | active not recruiting | Phase 3 | 1,600 | Daiichi SankyoINDUSTRY | 31 | May 15, 2026 | clinicaltrials |
| NCT04969835 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | recruiting | Phase 1 | 158 | Avacta Life Sciences LtdINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07589543 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer(EB-DUALNK-OV) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT04009148 | Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome | active not recruiting | — | 118 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06810141 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | available | — | — | ImmunityBio, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | suspended | — | 2,400 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05691504 | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | active not recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT02689427 | Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT02761889 | Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer | completed | N/A | 444 | Fundacao ChampalimaudOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07475325 | Individual Factors Associated With Care Pathways Delays in Breast Cancer in Hauts-de-France.(E-C-HAU) | active not recruiting | — | 500 | University Hospital, LilleOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04384770 | CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | active not recruiting | — | 179 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05284552 | Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer | recruiting | Phase 2 | 40 | University Hospital, LinkoepingOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03880422 | Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly Survivors of Advanced Prostate Cancer | recruiting | N/A | 50 | Roswell Park Cancer InstituteOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05154994 | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma(RESOLVE) | active not recruiting | Phase 1 | 9 | University of UtahOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | active not recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT05406232 | Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | recruiting | — | 36 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | recruiting | N/A | 25 | Jessica Mezzanotte SharpeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07568756 | Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation | not yet recruiting | Phase 2 | 60 | University of California, IrvineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT01411345 | MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial(MAPS) | active not recruiting | N/A | 37 | University of MiamiOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05271318 | Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.(PROTA) | active not recruiting | Phase 1 / Phase 2 | 29 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | May 5, 2026 | clinicaltrials |
| NCT06466382 | OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy(OVPrecision) | recruiting | N/A | 60 | Swiss GO Trial GroupNETWORK | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03393884 | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)(OVATION 2) | active not recruiting | Phase 1 / Phase 2 | 130 | ImunonINDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT04169542 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | recruiting | — | 600 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04245176 | Genetic Testing for All Breast Cancer Patients (GET FACTS) | completed | N/A | 400 | Brigham and Women's HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05551507 | IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT01245712 | Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer | active not recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 26, 2026source: clinicaltrials